1 February 2024 in EP Europace
Aims: Failure of radiofrequency (RF) ablation of ventricular arrhythmias is often due to inadequate lesion size. Irrigated RF ablation with half-normal saline (HNS) has the potential to increase lesion size and reduce sodium delivery to the patient if the same volume of RF irrigant were used for normal saline (NS) and HNS but could increase risks related to steam pops and lesion size. This study aims to assess periprocedural complications and acute ablation outcome of ventricular arrhythmias ablation with HNS. Methods and results: Prospective assessment of outcomes was performed in 1024 endocardial and/or epicardial RF ablation procedures in 935 consecutive patients (median age 64 years, 71.2% men, 73.4% cardiomyopathy, 47.2% sustained ventricular tachycardia). Half-normal saline was selected at the discretion of the treating physician. Radiofrequency ablation power was generally titrated to a ≤15 Ω impedance fall with intracardiac echocardiography monitoring. Half-normal saline was used in 900 (87.9%) and NS in 124 (12.1%) procedures. Any adverse event within 30 days occurred in 13.0% of patients treated with HNS RF ablation including 4 (0.4%) strokes/transient ischaemic attacks and 34 (3.8%) pericardial effusions requiring treatment (mostly related to epicardial access). Two steam pops with perforation required surgical repair (0.2%). Patients who received NS irrigation had less severe disease and arrhythmias. In multivariable models, adverse events and acute success of the procedure were not related to the type of irrigation. Conclusion: Half-normal saline irrigation RF ablation with power guided by impedance fall and intracardiac echocardiography has an acceptable rate of complications and acute ablation success while administering half of the saline load expected for NS irrigation.
19 March 2024 in Journal of Cardiovascular Electrophysiology
AKArvindh N. Kanagasundram
+4
Introduction: When ventricular tachycardia (VT) recurs after standard RF ablation (sRFA) some patients benefit from repeat sRFA, whereas others warrant advanced methods such as intramural needle ablation (INA). Our objectives are to assess the utility of repeat sRFA and to clarify the benefit of INA when repeat sRFA fails in patients with VT due to structural heart disease.Methods: In consecutive patients who were prospectively enrolled in a study for INA for recurrent sustained monomorphic VT despite sRFA, repeat sRFA was considered first. INA was performed during the same procedure if repeat sRFA failed or no targets for sRFA were identified.Results: Of 85 patients enrolled, acute success with repeat sRFA was achieved in 30 patients (35%), and during the 6‐month follow‐up, 87% (20/23) were free of VT hospitalization, 78% were free of any VT, and 7 were lost to follow‐up. INA was performed in 55 patients (65%) after sRFA failed, or no endocardial targets were found abolished or modified inducible VT in 35/55 patients (64%). During follow‐up, 72% (39/54) were free of VT hospitalization, 41% were free of any VT, and 1 was lost to follow‐up. Overall, 59 out of 77 (77%) patients were free of hospitalization and 52% were free of any VT. Septal‐origin VTs were more likely to need INA, whereas RV and papillary muscle VTs were less likely to require INA.Conclusions: Repeat sRFA was beneficial in 23% (18/77) of patients with recurrent sustained VT who were referred for INA. The availability of INA increased favorable outcomes to 52%.
9 May 2024 in Journal of Cardiovascular Electrophysiology
17 October 2025 in Journal of Arrhythmia
Background: Although immediate recurrence of atrial fibrillation (IRAF) after cardioversion has been proposed as a surrogate for atrial substrate vulnerability, its broad definition may insufficiently discriminate patients at highest risk of postablation recurrence. We introduced the concept of ultra‐early recurrence of AF (URAF)—defined as recurrence within 10 s after direct current cardioversion (CV) under deep sedation—as a novel marker of advanced remodeling in persistent atrial fibrillation (AF). Objective: To evaluate whether URAF independently predicts late recurrence following pulmonary vein isolation (PVI) in patients with persistent or long‐standing persistent AF. Methods: We retrospectively analyzed 104 patients undergoing first‐time PVI for persistent AF. Among 93 patients who underwent external CV, URAF, and IRAF were defined as AF recurrence within 10 and 90 s, respectively. Recurrence of atrial arrhythmias was assessed at 12 m postablation. Results: URAF was observed in 10/104 patients (9.6%) and was associated with higher 12‐m recurrence compared with URAF‐negative patients (50% vs. 18%, p = 0.02), whereas IRAF (20/104, 19.2%) showed no significant difference (30% vs. 19%, p = 0.28). On multivariable logistic regression, URAF (Odds Ratio (OR): 4.8; 95% Confidence Interval (CI): 1.16–19.98; p = 0.029) and long‐standing AF (OR: 5.5; 95% CI: 1.70–17.78; p = 0.004) emerged as independent predictors of recurrence. Kaplan–Meier analysis showed worse recurrence‐free survival for URAF (log‐rank p = 0.02; HR 4.5, 95% CI 1.18–17.41). Conclusion: URAF may represent a promising intra‐procedural marker associated with post‐ablation recurrence in persistent AF, but prospective validation in larger cohorts is required.